(Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer ...

BioNTech (NASDAQ:BNTX) has agreed to acquire its German rival CureVac (NASDAQ:CVAC) in an all-stock transaction worth nearly $1.25B, the companies announced Thursday. Shares of CureVac (NASDAQ:CVAC) ...

MUNICH (Reuters) - A German court on Tuesday invalidated a patent that was the basis of a patent violation lawsuit brought by CureVac against its domestic rival BioNTech, in a blow to CureVac's claims ...

German vaccine manufacturer BioNTech, which rose to global prominence with its Covid-19 vaccine developed alongside Pfizer, plans to close several production sites, with up to 1,860 jobs affected. The ...

German biopharmaceutical company CureVac sued BioNTech on Tuesday, seeking "fair compensation" for alleged infringement of intellectual property rights related to the mRNA technology that was used to ...

The German biotech is struggling to redefine itself post-Covid, and an oncology push is part of the solution.

BioNTech, once celebrated for its COVID-19 vaccines, is grappling with falling demand, restructuring and the departure of its ...

BEIJING (Reuters) -A shipment of BioNTech COVID-19 vaccines for German nationals in China have arrived at the German embassy in Beijing, an embassy spokesperson told Reuters on Friday. "We can now ...

BERLIN, Jan 11 (Reuters) - BioNTech 22UAy.DE has filed a motion to have a German patent held by competitor CureVac 5CV.DE declared invalid in response to a patent lawsuit filed by CureVac last year, a ...